Patents by Inventor Neil Anthony Pegg
Neil Anthony Pegg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11377443Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: GrantFiled: May 14, 2020Date of Patent: July 5, 2022Assignee: CELLCENTRIC LIMITEDInventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
-
Publication number: 20200407349Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: ApplicationFiled: May 14, 2020Publication date: December 31, 2020Inventors: Neil Anthony PEGG, Stuart Thomas ONIONS, David Michel Adrien TADDEI, Jonathan SHANNON, Silvia PAOLETTA, Richard James BROWN, Don SMYTH, Gareth HARBOTTLE
-
Patent number: 10696666Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: GrantFiled: October 18, 2017Date of Patent: June 30, 2020Assignee: CELLCENTRIC LIMITEDInventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
-
Patent number: 10647704Abstract: A compound which is a benzimidazole of formula (I): wherein X is a 5-membered heteroaryl group selected from the following: or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: GrantFiled: October 18, 2017Date of Patent: May 12, 2020Assignee: CELLCENTRIC LTDInventors: Neil Anthony Pegg, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Ting Qin, Gareth Harbottle
-
Publication number: 20190375740Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: ApplicationFiled: October 18, 2017Publication date: December 12, 2019Inventors: Neil Anthony PEGG, Stuart Thomas ONIONS, David Michel Adrien TADDEI, Jonathan SHANNON, Silvia PAOLETTA, Richard James BROWN, Don SMYTH, Gareth HARBOTTLE
-
Patent number: 10428065Abstract: A compound which is an isoxazolyl imidazopyridine of formula (I): wherein: R0 and R, which are the same or different, are each H or C alkyl; R9? and R9?, which are the same or different, are each H or F; X is -(alk)n-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R? and a 4- to 7-membered heterocyclic group which is unsubstituted or substituted; R2 and R2?, which are the same or different, are each H or C1-6 alkyl; or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3?, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer.Type: GrantFiled: April 20, 2016Date of Patent: October 1, 2019Assignee: CELLCENTRIC LTDInventors: Neil Anthony Pegg, David Michel Adrien Taddei, Richard Brown
-
Publication number: 20190263788Abstract: A compound which is a benzimidazole of formula (I): wherein X is a 5-membered heteroaryl group selected from the following: or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: ApplicationFiled: October 18, 2017Publication date: August 29, 2019Inventors: Neil Anthony PEGG, David Michel Adrien TADDEI, Jonathan SHANNON, Silvia PAOLETTA, Ting QIN, Gareth HARBOTTLE
-
Patent number: 10118920Abstract: A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0 and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R?; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2?, which are the same or different, are each H or C1-6 alkyl, or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: GrantFiled: April 20, 2016Date of Patent: November 6, 2018Assignee: CELLCENTRIC LTDInventors: Neil Anthony Pegg, David Michel Adrien Taddei, Stuart Thomas Onions, Eric Sing Yuen Tse, Richard James Brown, David Kenneth Mycock, David Cousin, Anil Patel
-
Publication number: 20180127402Abstract: A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0 and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R?; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2?, which are the same or different, are each H or C1-6 alkyl, or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.Type: ApplicationFiled: April 20, 2016Publication date: May 10, 2018Inventors: Neil Anthony PEGG, David Michel Adrien TADDEI, Stuart Thomas ONIONS, Eric Sing Yuen TSE, Richard James BROWN, David Kenneth MYCOCK, David COUSIN, Anil PATEL
-
Publication number: 20180105519Abstract: A compound which is an isoxazolyl imidazopyridine of formula (I): wherein: R0 and R, which are the same or different, are each H or C alkyl; R9? and R9?, which are the same or different, are each H or F; X is -(alk)n-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R? and a 4- to 7-membered heterocyclic group which is unsubstituted or substituted; R2 and R2?, which are the same or different, are each H or C1-6 alkyl; or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3?, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer.Type: ApplicationFiled: April 20, 2016Publication date: April 19, 2018Inventors: Neil Anthony PEGG, David Michel Adrien TADDEI, Richard BROWN
-
Patent number: 8697693Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: July 19, 2012Date of Patent: April 15, 2014Assignee: F. Hoffmann LaRoche AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohai
-
Publication number: 20120283257Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: ApplicationFiled: July 19, 2012Publication date: November 8, 2012Applicant: F. HOFFMANN-LA ROCHE AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohal
-
Patent number: 8293735Abstract: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: October 27, 2008Date of Patent: October 23, 2012Assignee: F. Hoffmann-La Roche AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Alan John Nadin, Stephen Price
-
Patent number: 8252792Abstract: Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.Type: GrantFiled: April 25, 2007Date of Patent: August 28, 2012Assignee: F. Hoffman-La Roche AGInventors: Stewart James Baker, Paul John Goldsmith, Timothy Colin Hancox, Neil Anthony Pegg, Stephen Price, Stephen Joseph Shuttleworth, Sukhjit Sohal
-
Patent number: 8168633Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: January 7, 2011Date of Patent: May 1, 2012Assignee: Genentech, Inc.Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110098270Abstract: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: January 7, 2011Publication date: April 28, 2011Inventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Jahusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110053935Abstract: Fused pyridines of formula (I) and the pharmaceutically acceptable salts thereof have activity as inhibitors of c-Met and may thus be used to treat various diseases and disorders including cancer. Processes for synthesizing the compounds are also described.Type: ApplicationFiled: January 26, 2009Publication date: March 3, 2011Inventors: Adrian John Folkes, Paul Goldsmith, Neil Anthony Pegg
-
Patent number: 7893060Abstract: Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; and R4 is an indole group which is unsubstituted or substituted; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PD kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: June 12, 2008Date of Patent: February 22, 2011Assignee: F. Hoffmann-La Roche AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Mandy Christine Beswick, Toby Jonathan Blench, Elsa Amandine Dechaux, Janusz Jozef Kulagowski, Alan John Nadin, Stephen Price
-
Publication number: 20110021496Abstract: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: ApplicationFiled: October 27, 2008Publication date: January 27, 2011Applicant: F. HOFFMANN-LA ROCHE AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Alan John Nadin, Stephen Price
-
Publication number: 20100267755Abstract: The invention provides the compounds of formula (I) and pharmaceutically acceptable salts thereof, in which: R1 and R2 are independently selected from the group consisting of H, C1-6alkyl, C1-2alkyl substituted by one to five fluorine atoms, C3-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl, C4-12bridged cycloalkyl, A(CR7R8)n and B(CR7R8)n; R3 is selected from the group consisting of C1-6alkyl, NH2 and R10CONH; R4 is C1-2alkyl substituted by one to five fluorine atoms; R5 is selected from the group consisting of H, C1-4alkyl, C1-2alkyl substituted with one to five fluorine atoms, halogen and C3-10cycloalkylC0-6alkyl, with the proviso that when R6 is H R5 is not H.Type: ApplicationFiled: May 23, 2002Publication date: October 21, 2010Applicants: GLAXO GROUP LIMITED, Jennifer Margaret GREENInventors: Gianpaolo Bravi, Malcolm Clive Carter, Richard Howard Green, Jennifer Margaret Doughty, Charles David Hartley, Alan Naylor, Martin Pass, Jeremy John Payne, Neil Anthony Pegg